Navigation Links
EpiCept Reports Regulatory Progress on Ceplene(TM)
Date:9/17/2007

ong term after relapse. There are currently no proven treatments for maintaining long-term remission for AML patients.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... WASHINGTON , Dec. 18, 2014 Since ... Road, the site now known as the leading online ... has seen explosive growth in its offering of drugs ... Citizens Alliance show the takedowns did succeed in lowering ... our last review of the markets in August. But ...
(Date:12/19/2014)... China separating membrane market has witnessed robust development ... years, albeit as a later starter. In 2012, the size ... approximated RMB12 billion, with the proportion worldwide soaring to 16.3%. ... membrane market will continue its growth rate by around 20% ... will jump to roughly RMB25 billion. An integrated ...
(Date:12/17/2014)... , December 17, 2014 Revenue and ... expenditure on research and development In the past ... revenue by two percent to EUR 4.287 billion (last year: ... by 14 percent to EUR 360 million. "Overall, 2013/14 was ... Michael Kaschke , President and CEO of Carl Zeiss ...
Breaking Medicine Technology:Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS Asserts its Position in Difficult Environment 2
(Date:12/19/2014)... 2014 After a 13-year absence from ... returning to the stage to entertain his many worldwide ... performances, and the successful tour has been steadily expanding ... , Visit Ticketability.com for a large inventory ... at fair prices. , Music fans have had a ...
(Date:12/19/2014)... The Hermitage Club at Haystack ... Vermont’s Deerfield Valley, announced today that it has unveiled ... songs. , Three time Grammy Award Winner Kenny ... followed by a trail naming ceremony. Hermitage Club Founder, ... “I’m Alright” the theme song for the movie soundtrack ...
(Date:12/19/2014)... News) -- The tragic death from "rat-bite fever" of a ... pet rodents, according to a report from the U.S. Centers ... rare but potentially fatal illness that should be considered in ... history of rodent exposure is reported," said a team led ... The case outlined in the report occurred in August ...
(Date:12/19/2014)... (HealthDay News) -- Traveling through the same U.S. airport ... three others within a four-hour time span, illustrating just ... shows. "The exposures in this report were not ... international terminal, highlighting the fact that measles is highly ... infectious disease specialist at the U.S. Centers for Disease ...
(Date:12/17/2014)... While countless companies tempt patients to buy hCG ... of their purchase. Not only is the sale of hCG ... patients who buy hCG online are typically receiving products that ... real hCG present. Illegal internet hCG is typically manufactured outside ... and may contain unknown fillers that can pose very serious ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Scratch From Pet Rat Kills Child; CDC Warns of Risk 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3
... CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) has received ... for the Company on the OTCBB will take place at ... The new ticker symbol for "CardioGenics Holdings Inc." on the ... name and ticker symbol change that is scheduled to take ...
... (Nasdaq: AKRX ) will release third quarter 2009 earnings Tuesday, November 10, before the market ... results followed by a Q&A session: , , Subject: ... Date/Time: ... ...
... waists in men spell trouble, study finds , MONDAY, Oct. ... appears to affect the risk of dangerous blood clots in ... new Danish study indicates. , The 10-year study found that ... thromboembolism (VTE) in women but not men, while a wider ...
... Some simple precautions will safeguard young trick-or-treaters, experts say ... trick to keeping children and the rest of the ... that the night is a treat for everyone. , ... tips: , Choose costumes that are bright and ...
... BOSTON, Oct. 26 Uno Chicago Grill®, America,s Healthiest Chain ... limited-time-only fall menu. , This exciting fall menu ... cranberries are a well-known and popular accent to many dishes, ... once the territory of a select few health food aficionados. ...
... , CENTENNIAL, Colo., Oct. 26 LABS Inc., one ... the country, announced today that it will begin offering ... transfusion medicine and blood services industry. LABS Inc.,s acquisition ... expertise to blood collection programs nationwide. , LABS Inc. ...
Cached Medicine News:Health News:Where You Put on Pounds May Influence Clot Risk 2Health News:Treat Kids to a Safe Halloween 2Health News:Go, Go, Goji! UNO(R) Fall Menu Is 'Berry' Delicious 2Health News:Go, Go, Goji! UNO(R) Fall Menu Is 'Berry' Delicious 3Health News:LABS Inc. to Offer Donor Testing Services for Transfusion Medicine and Blood Services Industry 2
... pH: pH(4.7%, H 2 O): 7.0 ... 47% Potassium Phosphate Dibasic: 25% Potassium Phosphate Monobasic: ... powder per liter of purified water. Autoclave. Application: ... proteins than LB media by allowing for greater ...
1.2% Tryptone, 2.4% Yeast Extract, 0.4% Glycerol, with 100ml of 10x Phosphate buffer supplement (0190-01)....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
3.2% Tryptone, 2.0% Yeast Extract, 0.5% Sodium Chloride, pH 7.5....
Medicine Products: